TIGIT competes with CD226 for binding with CD155 expressed on antigen-presenting cells, and this results in immune suppression based on both competitive interaction and TIGIT-mediated intracellular signaling. TIGIT is an emerging checkpoint inhibitor and blocking CD155:TIGIT interaction represents an attractive therapeutic strategy in cancer immunotherapy.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.